Exploratory study for the efficacy and safety of Yokukansankachimpihange on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD).

Exploratory study for the efficacy and safety of Yokukansankachimpihange on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD). - The exploratory study of Yokukansankachimpihange on BPSD in patients with AD.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018369

Enrollment

Registered

2015-08-01

Start date

2015-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AD patients with BPSD

Interventions

Yokukansankachimpihange treatment for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) probable AD 2) Within normal limit of serum potassium. 3) Have a study partner able to provide an independent evaluation of functioning. 4) Agreement to sign an informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with neurological disease to affect the cognitive function except AD. 2) Patients who have local lesion which affected the cognitive function by CT or MRI. 3) Patients with serious diseases such as malignant tumors, or disorder which is not in stable condition. 4) Patient who has an allergy to Kampo medicine. 5) Patients considered inappropriate by the study investigator.

Design outcomes

Primary

Measure	Time frame
Changes in neuropsychiatric inventory (NPI) total score before and after Yokukansankachimpihange treatment	—

Secondary

Measure	Time frame
Changes in neuropsychiatric inventory (NPI) subscale score before and after Yokukansankachimpihange treatment	—

Countries

Japan

Contacts

Public ContactRyutaro Arita

Keio University School of Medicine Center for Kampo Medicine

tarikun@a6.keio.jp03-5366-3824

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Exploratory study for the efficacy and safety of Yokukansankachimpihange on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer&#39;s disease (AD).